Global Rheumatology Drugs Market Outlook, 2031

The global rheumatology drugs industry covers medicines used to treat inflammatory and autoimmune diseases of the joints, muscles, bones and connective tissues, including rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, systemic lupus erythematosus and lupus nephritis, gout, osteoarthritis, osteoporosis, Sjögren's disease, systemic sclerosis, vasculitis such as giant cell arteritis, polymyalgia rheumatica, juvenile idiopathic arthritis and inflammatory myopathies. Treatments include conventional disease-modifying antirheumatic drugs such as methotrexate, sulfasalazine, leflunomide and hydroxychloroquine; biologic drugs targeting TNF, IL-6, IL-17, IL-23, CD20, CD80/86 and B-cell activating factor; targeted synthetic drugs such as JAK inhibitors; corticosteroids; non-steroidal anti-inflammatory drugs; urate-lowering therapies for gout; and bone-building and anti-resorptive drugs for osteoporosis. Leading companies include AbbVie, with Humira and Rinvoq; Amgen, with Enbrel, Otezla, Prolia and Evenity and Krystexxa after acquiring Horizon; Johnson & Johnson, with Simponi, Stelara and Tremfya; Novartis, with Cosentyx; UCB, with Cimzia, Bimzelx and Evenity with Amgen; Pfizer, with Xeljanz; Eli Lilly, with Taltz and Olumiant; Bristol Myers Squibb, with Orencia; Roche, with Actemra and Gazyva; GSK, with Benlysta; AstraZeneca, with Saphnelo; Sanofi and Regeneron, with Kevzara; and Aurinia, with Lupkynis. Biosimilar makers, including Amgen, Sandoz, Celltrion, Samsung Bioepis, Fresenius Kabi and Biocon, have become major suppliers of adalimumab, etanercept, infliximab, rituximab, tocilizumab and denosumab.

Rheumatology was the first therapeutic area to experience large-scale biosimilar competition, and this has reshaped the market since 2020. Adalimumab biosimilars launched in Europe in 2018 and in the United States from January 2023, where pharmacy benefit managers began favouring private-label versions in 2024, cutting Humira sales sharply. Tocilizumab, rituximab, infliximab and denosumab biosimilars followed, and Medicare negotiated prices for Enbrel and Stelara took effect in January 2026. Growth has shifted to newer drugs. Rinvoq, a JAK inhibitor, expanded across rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis and giant cell arteritis, approved in April 2025, despite boxed safety warnings for the class issued in 2021 after the ORAL Surveillance trial. UCB's Bimzelx, which blocks both IL-17A and IL-17F, gained US approvals for psoriatic arthritis and axial spondyloarthritis in September 2024. Lupus has seen renewed progress, with Roche's Gazyva approved for lupus nephritis in October 2025, several late-stage programmes in systemic lupus and Sjögren's disease, and CAR-T cell therapy producing drug-free remissions in small studies of severe lupus, myositis and systemic sclerosis. In osteoporosis, Prolia biosimilars launched in 2025, while gout treatment remains dominated by generic allopurinol and febuxostat, with Krystexxa for refractory disease.

Market Dynamics Market Drivers • Rising Prevalence of Rheumatic and Autoimmune DiseasesRheumatic and musculoskeletal diseases affect hundreds of millions of people worldwide and are leading causes of pain and disability. Rheumatoid arthritis affects about 18 million people, gout is increasing with obesity and diet, osteoarthritis and osteoporosis rise with ageing populations, and autoimmune diseases such as lupus are increasingly diagnosed. Growing awareness and access to rheumatologists increase the number of treated patients.
• Treat-to-Target Strategies and Expanding IndicationsGuidelines recommend early, aggressive treatment aimed at remission or low disease activity, leading more patients to move to biologics and targeted synthetic drugs when conventional therapy fails. Successful drugs are being tested and approved across multiple rheumatic diseases, including giant cell arteritis, polymyalgia rheumatica, Sjögren's disease and lupus nephritis. Advanced therapies for previously underserved conditions are expanding the treated population.

Market Challenges • Biosimilar Erosion and Price ControlsBiosimilars for adalimumab, etanercept, infliximab, rituximab, tocilizumab and denosumab have reduced prices by large amounts, especially in Europe, and increasingly in the United States as pharmacy benefit managers favour lower-cost versions. Medicare price negotiation has reduced prices for Enbrel from 2026, and more rheumatology drugs are likely to be selected. Payers use step therapy to require cheaper drugs first, slowing uptake of newer branded treatments.
• Safety Concerns and Incomplete ResponsesJAK inhibitors carry boxed warnings for serious infections, major cardiovascular events, blood clots, cancer and death, limiting their use in older and higher-risk patients. Biologics increase infection risks. Many patients with rheumatoid arthritis do not achieve remission, and lupus, systemic sclerosis and Sjögren's disease remain difficult to treat. Long-term steroid use causes significant side effects, and treatment options for osteoarthritis remain mainly symptomatic.

Market Trends • Cell Therapies and Immune Reset in Autoimmune DiseaseCD19-directed CAR-T cell therapies have produced long-lasting drug-free remissions in small studies of refractory lupus, myositis and systemic sclerosis. Companies including Kyverna, Cabaletta, Novartis, Bristol Myers Squibb, Autolus and many Chinese developers are running trials, and T-cell engaging bispecific antibodies and in vivo CAR-T approaches are being studied as more scalable alternatives. These therapies could change the treatment paradigm for severe autoimmune disease.
• New Mechanisms for Lupus, Sjögren's Disease and VasculitisRheumatology pipelines increasingly target diseases with few approved treatments. Anti-CD20 antibodies, type I interferon blockers, CD40 ligand antagonists, FcRn blockers, BAFF and APRIL inhibitors and TYK2 inhibitors are in late-stage trials for lupus and Sjögren's disease. IL-6, IL-17, JAK and IL-23 inhibitors are being tested in vasculitis and polymyalgia rheumatica. Approvals in these areas would expand the specialist rheumatology market.



Segment Analysis Biologics account for the largest share of rheumatology drug value, while targeted synthetic drugs such as JAK inhibitors are growing and conventional drugs dominate prescription volume. Biologic disease-modifying antirheumatic drugs include TNF inhibitors such as adalimumab, etanercept, infliximab, certolizumab pegol and golimumab; IL-6 inhibitors such as tocilizumab and sarilumab; IL-17 inhibitors such as secukinumab, ixekizumab and bimekizumab; IL-23 and IL-12/23 inhibitors used in psoriatic arthritis; the T-cell co-stimulation modulator abatacept; the anti-CD20 antibodies rituximab and obinutuzumab; and lupus biologics such as belimumab and anifrolumab. Biologics generate the largest share of rheumatology revenue, although TNF inhibitor revenue has fallen with biosimilars. Targeted synthetic drugs, including JAK inhibitors such as upadacitinib, tofacitinib, baricitinib and filgotinib, and the PDE4 inhibitor apremilast, are taken orally and have grown despite safety warnings. Conventional synthetic drugs, including methotrexate, hydroxychloroquine, sulfasalazine and leflunomide, are the first-line treatment for most inflammatory arthritis and are widely used as low-cost generics. Corticosteroids and NSAIDs relieve inflammation and pain. Urate-lowering drugs, including allopurinol, febuxostat and pegloticase, and anti-inflammatory drugs such as colchicine treat gout. Osteoporosis drugs include bisphosphonates, denosumab, romosozumab, teriparatide and abaloparatide. Calcineurin inhibitors such as voclosporin treat lupus nephritis.

Rheumatoid arthritis is the largest rheumatology indication by value, while spondyloarthritis, lupus and osteoporosis are major segments and vasculitis and Sjögren's disease are emerging areas. Rheumatoid arthritis is the largest indication for advanced rheumatology drugs, with most biologics and JAK inhibitors approved for it, and many patients cycle through several treatments. Psoriatic arthritis and axial spondyloarthritis, including ankylosing spondylitis, are major indications for TNF, IL-17 and IL-23 inhibitors and JAK inhibitors, and IL-17 inhibitors have become key options. Systemic lupus erythematosus and lupus nephritis are treated with hydroxychloroquine, steroids, immunosuppressants, belimumab, anifrolumab, voclosporin and obinutuzumab, and they are areas of high unmet need with many trials. Gout is common and increasing, treated mainly with generic urate-lowering drugs, while pegloticase serves patients with refractory disease. Osteoporosis affects hundreds of millions of people, mainly older women, and is treated with generic bisphosphonates and branded injectables. Osteoarthritis is the most common joint disease, but treatment is mainly for pain, with no approved disease-modifying drugs. Giant cell arteritis and polymyalgia rheumatica gained approved biologic and JAK inhibitor options. Sjögren's disease, systemic sclerosis, myositis, juvenile idiopathic arthritis and ANCA-associated vasculitis are additional segments with growing drug development.

Subcutaneous injections account for the largest share of rheumatology biologic use, while oral drugs are growing and intravenous infusions remain important for certain biologics. Subcutaneous injections, given by patients at home using prefilled pens and syringes, are the main route for adalimumab, etanercept, certolizumab, golimumab, secukinumab, ixekizumab, bimekizumab, subcutaneous tocilizumab and abatacept, sarilumab, belimumab and denosumab, and they account for the largest share of biologic value. Dosing ranges from weekly to every one to two months, and longer intervals are a competitive advantage. Oral drugs include conventional DMARDs, JAK inhibitors, apremilast, steroids, NSAIDs, urate-lowering drugs and bisphosphonates, and oral targeted drugs are gaining share because many patients prefer tablets. Intravenous infusions are used for infliximab, rituximab, obinutuzumab, intravenous tocilizumab and abatacept, anifrolumab, pegloticase and zoledronic acid, delivered in hospitals and infusion centres. Intra-articular injections of steroids and hyaluronic acid treat osteoarthritis and inflamed joints. Topical NSAIDs treat localised pain. Subcutaneous formulations of drugs previously given intravenously, such as subcutaneous infliximab and anifrolumab, are being introduced to reduce infusion visits. CAR-T cell therapies, if approved for autoimmune disease, would be given as one-time infusions.

Specialty and retail pharmacies distribute most rheumatology drugs in the United States, while hospital pharmacies and national procurement play larger roles in Europe and Asia. Specialty pharmacies dispense most self-injected rheumatology biologics and oral targeted drugs in the United States, managing prior authorisation, copay support and delivery, and they are often owned by pharmacy benefit managers that choose preferred biosimilars. Retail pharmacies dispense conventional DMARDs, NSAIDs, steroids, gout and osteoporosis drugs. Hospital pharmacies and infusion centres supply intravenous biologics and treat severe or complex cases. Rheumatology practices in the United States often operate their own infusion suites and purchase drugs directly, a model known as buy and bill. In Europe, hospitals frequently dispense biologics for home use, and national and regional tenders drive rapid biosimilar adoption, with some countries switching most patients to biosimilars within months. Online and mail-order pharmacies are used for chronic oral medications. Government procurement and national reimbursement negotiations shape access in China and other Asian countries. Manufacturer patient support programmes provide training, nurse support and financial assistance. Osteoporosis drugs are also distributed through primary care and women's health clinics.

Regional Analysis North America leads the rheumatology drugs market because of high prices, broad use of biologics and targeted drugs, and early adoption of new therapies, while Europe has the most advanced biosimilar adoption and Asia-Pacific is the fastest-growing region. North America, led by the United States, accounts for the largest share of rheumatology drug revenue. The United States has high use of advanced therapies, high prices and a large number of rheumatologists, and it was the largest market for Humira before biosimilars arrived in 2023. Pharmacy benefit managers' adoption of private-label adalimumab biosimilars in 2024 and Medicare's negotiated price for Enbrel from 2026 have reduced revenue from older drugs, while Rinvoq, Cosentyx, Bimzelx and Taltz have grown. The FDA approved Rinvoq for giant cell arteritis in April 2025 and Gazyva for lupus nephritis in October 2025. Canada has high biosimilar uptake after provincial switching policies. Europe is the second largest market, with strong use of biologics at lower prices and the world's most advanced biosimilar adoption, driven by tenders in the Nordic countries, the UK, the Netherlands and Germany. Asia-Pacific is the fastest-growing region, with large patient populations in China, Japan and India. Japan has a large rheumatology market and high biologic use, while China has expanded access to biologics and JAK inhibitors through national reimbursement negotiations and has a growing domestic biosimilar and CAR-T industry, with Chinese groups among the leaders in CAR-T trials for lupus. India relies mainly on conventional DMARDs and biosimilars. Latin America, led by Brazil and Mexico, uses public procurement to access biologics and biosimilars, while the Middle East has growing rheumatology services in the Gulf states.

Key Developments January 2026: The first Medicare negotiated prices under the Inflation Reduction Act took effect, including lower prices for Amgen's Enbrel, a major rheumatoid arthritis drug.
October 2025: Roche's obinutuzumab was approved in combination with standard therapy for adults with active lupus nephritis, adding an anti-CD20 option for the disease.
April 2025: AbbVie's upadacitinib became the first oral JAK inhibitor approved for giant cell arteritis, a form of vasculitis affecting older adults.
2025: Biosimilars to Prolia and Xgeva entered the US market, reducing prices for one of the most widely used osteoporosis treatments.
September 2024: UCB's bimekizumab, which inhibits both IL-17A and IL-17F, was approved for psoriatic arthritis and axial spondyloarthritis in the United States.
January 2023: Amgen's Amjevita became the first adalimumab biosimilar in the United States, beginning the erosion of the world's former best-selling drug.

Considered in this report
• Historic Year: 2020
• Base Year: 2025
• Estimated Year: 2026
• Forecast Year: 2031

Aspects covered in this report
• Global Rheumatology Drugs Market with its value and forecast along with its segments
• Various drivers and challenges
• Ongoing trends and developments
• Top profiled companies
• Strategic recommendation

By Drug Class
• Biologic DMARDs
• Targeted Synthetic DMARDs
• Conventional Synthetic DMARDs
• Corticosteroids and NSAIDs
• Urate-Lowering Therapies
• Osteoporosis Drugs

By Indication
• Rheumatoid Arthritis
• Psoriatic Arthritis
• Axial Spondyloarthritis
• Systemic Lupus Erythematosus
• Gout
• Osteoporosis
• Other Rheumatic Diseases

By Route of Administration
• Subcutaneous
• Oral
• Intravenous
• Other

By Distribution Channel
• Specialty Pharmacies
• Retail Pharmacies
• Hospital Pharmacies
• Online Pharmacies